Results 21 to 30 of about 8,420 (208)

Looking for an optimal antihypertensive combination. Focus on azilsartan medoxomil/chlorthalidone [PDF]

open access: yesРоссийский кардиологический журнал
The article analyzes data from clinical studies on the efficacy and safety of azilsartan medoxomil/chlorthalidone combination and its components. According to the analyzed sources, both individual components and their combination have proven their ...
M. D. Smirnova   +2 more
doaj   +2 more sources

Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis

open access: yesDrug Design, Development and Therapy, 2015
Philipp Sievers,1 Lorenz Uhlmann,2 Sevil Korkmaz-Icöz,3 Christian Fastner,1 Florian Bea,1 Erwin Blessing,1 Hugo A Katus,1 Michael R Preusch11Department of Internal Medicine III, 2Institute of Medical Biometry and Informatics, 3Department of ...
Sievers P   +7 more
doaj   +1 more source

EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE

open access: yesРоссийский кардиологический журнал, 2011
Most patients with hypertension require more than one agent to control blood pressure (BP). The purpose of this study was to assess the efficacy and safety of the angiotensin II receptor blocker olmesartan medoxomil in combination with ...
Steven G. Chrysant   +3 more
doaj   +1 more source

Formulation and Evaluation of Olmesartan Medoxomil Tablets

open access: yesCompounds, 2022
This work proposes a methodology for the design, development, and characterization of tablets prepared by the direct compression method of olmesartan medoxomil. The main objective was to ensure a high dissolution rate of the active ingredient. Therefore,
R. González, M. A. Peña, G. Torrado
semanticscholar   +2 more sources

ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS

open access: yesРоссийский кардиологический журнал, 2011
Olmesartan medoxomil is a new angiotensin II receptor blocker. In this randomized, double-blind, placebo-controlled study, the efficacy and safety of olmesartan medoxomil was assessed in 334 patients with moderate to severe essential hypertension ...
J. M. Neutel   +4 more
doaj   +1 more source

Effect of angiotensin receptor blockade on endothelial function: focus on olmesartan medoxomil

open access: yesVascular Health and Risk Management, 2009
Carlos FerrarioHypertension and Vascular Disease Center, Wake Forest University School of Medicine, Winston-Salem, NC, USAAbstract: Endothelial dysfunction is the common link between cardiovascular disease risk factors and the earliest event in the ...
Carlos Ferrario
doaj   +1 more source

UV Spectrophotometric Determination of Hydrochlorothiazide and Olmesartan Medoxomil in Pharmaceutical Formulation

open access: yesE-Journal of Chemistry, 2010
A simple, specific, accurate, precise and reproducible method has been developed and validated for the simultaneous estimation of hydrochlorothiazide and Olmesartan medoxomil in combined dosage form by UV spectrophotometric method.
A. T. Hemke   +4 more
doaj   +2 more sources

Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong) [PDF]

open access: yesDrug Design, Development and Therapy, 2016
Jin-Sun Park,1,* Joon-Han Shin,1,* Taek-Jong Hong,2 Hong-Seog Seo,3 Wan-Joo Shim,4 Sang-Hong Baek,5 Jin-Ok Jeong,6 Youngkeun Ahn,7 Woong-Chol Kang,8 Young-Hak Kim,9 Sang-Hyun Kim,10 Min-Su Hyon,11 Dong-Hoon Choi,12 Chang-Wook Nam,13 Tae-Ho Park,14 Sang ...
Park JS   +16 more
doaj   +2 more sources

Recent Analytical Methods for <i>N-</i>Nitrosamine Analysis as Impurities in Drug Substances and Drug Products. [PDF]

open access: yesJ Anal Methods Chem
N‐nitrosamine (hereinafter nitrosamine) is among the organic impurities characterized by high potency as genotoxic and probable human carcinogens found in drug substances and drug products. This type of impurity has become a major concern in pharmaceutical industry, since one of nitrosamine type of impurities, NDMA, was detected in valsartan active ...
Pratiwi R   +3 more
europepmc   +2 more sources

Benzbromarone as a Novel Candidate for Preventing Alzheimer's Disease: Evidence From Real-World Data Screening and in Vitro Validation. [PDF]

open access: yesClin Transl Sci
Drug repositioning analysis identifies candidate therapeutic agents for Alzheimer’s diseaseand supports further mechanistic and translational investigation. ABSTRACT Drug development for Alzheimer's disease (AD) remains challenging, with only a 0.4% success rate from Phase I trials to regulatory approval.
Sakagami S   +11 more
europepmc   +2 more sources

Home - About - Disclaimer - Privacy